Skip to Content

Brisdelle Approval History

FDA Approved: Yes (First approved June 28, 2013)
Brand name: Brisdelle
Generic name: paroxetine mesylate
Dosage form: Capsules
Company: Noven Pharmaceuticals, Inc.
Treatment for: Postmenopausal Symptoms

Brisdelle (paroxetine mesylate) is a low-dose selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Development History and FDA Approval Process for Brisdelle

DateArticle
Jun 28, 2013Approval FDA Approves Brisdelle - First Non-Hormonal Treatment for Hot Flashes Associated with Menopause
Mar  6, 2013Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
Nov 14, 2012FDA Accepts Noven's NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
Aug 29, 2012Noven Submits New Drug Application for Investigational Non-Hormonal Therapy for Menopausal Vasomotor Symptoms

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide